US Insulin Delivery Is Changing: The GLP-1 Impact Manufacturers Cannot Ignore

Something should concern every manufacturer in the US insulin pen needle and syringe market right now. A company with dominant US market share has confirmed in its own SEC filing that GLP-1 drug penetration is delaying insulin initiation and reducing device demand. A single major retail customer shifted to a lower-cost competitor, moving revenue by double digits. More than 30 pharma partnerships are in the pipeline for GLP-1 co-packaging. Market-appropriate pen needles remain under FDA review. And a $100M+ opportunity depends on patent timelines, regulatory approvals, and patient adoption curves aligning. Digital Sonar™ by Apex Metrics tracks this market across five signal layers—and the gaps are sharper than most internal teams realise. Patient behaviour is more complex than a simple switch. A measurable cohort of insulin-dependent diabetics starting GLP-1 therapy continues using pen needles for concurrent insulin, creating dual-device behaviour that distorts demand forecasts across the category. HCP prescribing is not uniform. Behaviour across the GLP-1 and insulin adjacency varies by specialty, geography, and patient cohort. Yet existing commercial intelligence often misses this variation at account level. Retail dynamics are moving faster than commercial tracking. The shift toward low-cost pen needle alternatives across major US pharmacy and retail accounts is uneven. Some accounts have moved decisively; others remain in negotiations. Most manufacturers cannot distinguish between them. The $100M GLP-1 co-packaging opportunity is real. But which of the 30+ partners reaches market first, through which US channel, at what price point, and with what prescriber pull-through? These remain critical unanswered questions for revenue teams. Apex Metrics continuously tracks patient-level behaviour signals, HCP prescription pattern shifts, retail channel dynamics, competitor product pipeline timing, and formulary movement across the US insulin delivery ecosystem—not quarterly. If your commercial decisions rely on data that is already a quarter old, you may be operating behind the market's current reality.

Apex Metrics

10/27/20261 min read

US Insulin Delivery Is Changing: The GLP-1 Impact Manufacturers Cannot IgnorePredict the future

Something that should concern every manufacturer in US insulin pen needles and syringes right now.

A company with dominant US market share has now confirmed in its own SEC filing that GLP-1 drug penetration is delaying insulin initiation and reducing device demand. A single major retail customer shifted to a lower-cost competitor — and it moved the revenue needle by double digits. Thirty-plus pharma partnerships in the pipeline for GLP-1 co-packaging. Market-appropriate pen needles still under FDA review. And a $100M+ opportunity that arrives only if patent timelines, regulatory approvals, and patient adoption curves all line up exactly right.

Digital Sonar™ by Apex Metrics has been tracking this market across five signal layers — and the gaps are sharper than most internal teams realise.

Patients are not switching cleanly. A measurable cohort of insulin-dependent diabetics starting GLP-1 therapy is continuing to use pen needles for concurrent insulin — creating a dual-device behaviour that distorts demand forecasting for every player in this category.

HCPs are not prescribing uniformly. Prescriber behaviour across the GLP-1 and insulin adjacency varies significantly by specialty, geography, and patient cohort — and none of the commercial intelligence currently used by manufacturers in this space captures that variation at account level.

The retail channel is moving faster than commercial teams are tracking. The shift to low-cost pen needle alternatives at major US pharmacy and retail accounts is not evenly distributed. Some accounts have moved decisively. Others are mid-negotiation. Most manufacturers cannot tell the difference.

The $100M GLP-1 co-packaging opportunity is real. But which of 30+ partners reaches market first, in which US channel, at what price point, and with which prescriber pull-through — none of that is known to the people whose revenue depends on it.

Apex Metrics tracks patient-level behaviour signal, HCP prescription pattern shifts, retail channel dynamics, competitor product pipeline timing, and formulary movement across the US insulin delivery ecosystem — continuously, not quarterly.

If you are making commercial decisions in this space on data that is a quarter old, you are already behind where the market is today.

My post content